

## **QluCore Omics Explorer helps Immunovia to easily perform complex data analysis**

[QluCore](#), a leader in the development of bioinformatics visualization software, announces that [Immunovia](#), an innovative diagnostic company that has successfully developed a blood-based test for early diagnosis of pancreatic cancer using antibody biomarker microarray analysis, has chosen to use QluCore Omics Explorer for data analysis.

“At Immunovia we routinely explore and analyse large data sets within our research and development. QluCore Omics Explorer is helping us to perform complex analysis smoothly and correctly, thanks to its powerful functions and intuitive GUI. Since the software has proved very reliable and stable, it forms an integral part of our research work,” says Mats Grahn, CEO at Immunovia.

“At QluCore we are very happy to have Immunovia as a customer to support them in their forefront work in cancer and autoimmune diseases diagnostics,” says Carl-Johan Ivarsson, QluCore President.

### **ABOUT IMMUNOVIA**

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia’s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: [www.immunovia.com](http://www.immunovia.com))

Immunovia’s shares (IMMNOV) are listed **on Nasdaq First North in Stockholm and Wildecó is the company’s Certified Adviser. For more information, please visit [www.immunovia.com](http://www.immunovia.com).**